Peptide blends: what a combined vial actually contains

How a blend is specified

A blend is described by its components and their nominal masses — for example a vial containing 5 mg of one peptide and 5 mg of another. The ratio matters as much as the total, because a working solution delivers both components at once.

Read the stated masses rather than the product name. A name that lists two compounds says nothing about the proportion in the vial.

Each component needs its own numbers

• Assayed content should be reported separately for each peptide, not as a combined total.
• Purity should be reported per component where the analytical method resolves them.
• The chromatogram should show distinct, well-separated peaks for the components.
• Where two components co-elute, the report cannot support a per-component purity claim and should say so.

Reconstitution maths gets harder

Adding 2 mL of diluent to a vial containing 5 mg and 5 mg gives 2.5 mg/mL of each component — but only if the assayed content matches the nominal masses. Where the assay shows 4.6 mg and 5.8 mg, your actual concentrations diverge and every downstream calculation inherits that.

Work from the assayed figures on the certificate rather than the label when accuracy matters.

Trade-offs in experimental design

• You cannot vary the components independently once they share a vial.
• Stability of the blend is governed by its least stable component.
• Attributing an observed effect to one component is not possible without separate single-compound controls.
• Fewer vials and one reconstitution step is the genuine upside — convenience, not experimental rigour.

When to buy separates instead

If the experiment needs dose-response data on either component, or needs to attribute an effect, buy the peptides separately and combine at the bench. Blends suit workflows where the combination itself is the object of study and the ratio is fixed by design.